Wednesday, September 23, 2026

USD/CNH Over 1% Up In The Last 5 Sessions

USD/CNH Over 1% Up In The Last 5 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.69% for the last 5 sessions. At 15:06 EST on Sunday, 24 March, USD/CNH (USDCNH) is $7.27.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

News about

  • According to FXStreet on Friday, 22 March, "Apart from this, some follow-through US Dollar (USD) buying interest should help limit the downside for the USD/JPY pair.", "This, along with the prevalent risk-on environment, which tends to dent demand for the safe-haven JPY, favours the USD/JPY bulls. "
  • It is only a matter of time before usd/jpy makes new cyclical highs – BBH. According to FXStreet on Friday, 22 March, "Bottom line: we think it's only a matter of time before USD/JPY makes new cyclical highs."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com